Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP

Starting soon · Phase 4

Conditions studied: Pityriasis Rubra Pilaris

In brief

The purpose of this study is to valuate the clinical efficacy of Bimzelx therapy in adults with Pityriasis Rubra Pilaris.

Key facts

Study ID

NCT07497620

Run by

Mayo Clinic

People needed

12

Starts

2026-07-01

Expected to finish

2027-12-01

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical and/or histopathological diagnosis of PRP
• Candidate for systemic therapy (PASI ≥ 10)
• Body surface area of involvement ≥ 10%
• Good general health as confirmed by medical history
• Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and
• Patients who read and sign an approved informed consent for this study

You may not qualify if…

• Vulnerable study population
• Pregnant or nursing women
• Women planning a pregnancy within the study period
• Human immunodeficiency virus (HIV) positivity
• Known history of adverse reaction to Bimzelx
• Known history of hepatitis B, hepatitis C, or tuberculosis
• Personal or family history of inflammatory bowel disease

Where it is running

• Mayo Clinic in Florida — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.